Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Change in Account Payables: 2020-2025

Historic Change in Account Payables for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to -$9.3 million.

  • Arcutis Biotherapeutics' Change in Account Payables fell 242.76% to -$9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.5 million, marking a year-over-year decrease of 847.59%. This contributed to the annual value of $2.2 million for FY2024, which is 29.28% down from last year.
  • Per Arcutis Biotherapeutics' latest filing, its Change in Account Payables stood at -$9.3 million for Q3 2025, which was down 1,776.53% from $554,000 recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Change in Account Payables ranged from a high of $6.5 million in Q3 2024 and a low of -$9.3 million during Q3 2025.
  • Moreover, its 3-year median value for Change in Account Payables was $309,000 (2025), whereas its average is -$276,727.
  • As far as peak fluctuations go, Arcutis Biotherapeutics' Change in Account Payables slumped by 1,931.34% in 2023, and later spiked by 263.71% in 2024.
  • Quarterly analysis of 5 years shows Arcutis Biotherapeutics' Change in Account Payables stood at $2.4 million in 2021, then tumbled by 92.39% to $182,000 in 2022, then tumbled by 755.49% to -$1.2 million in 2023, then soared by 91.20% to -$105,000 in 2024, then tumbled by 242.76% to -$9.3 million in 2025.
  • Its Change in Account Payables stands at -$9.3 million for Q3 2025, versus $554,000 for Q2 2025 and $309,000 for Q1 2025.